Literature DB >> 7057802

Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. II. Development of heart necrotic changes in relation to defective mitochondrial function.

L Proschek, G Jasmin.   

Abstract

The mitochondrial oxidative phosphorylation, calcium and magnesium contents, and swelling-contraction activity were investigated in relation to the progression of the hereditary hamster cardiomyopathy. The assessment was made in animals between 22 and 232 days of age, which were divided into 7 groups according to stage of disease. In 24-day-old hamsters prior to development of heart necrotic changes, the membrane permeability of isolated mitochondria was altered. In 50-day-old animals, at a stage of disease when myocardial cells undergo degeneration, a defect of oxidative phosphorylation resulting from an increase in mitochondrial calcium was demonstrated. With culmination of the heart necrotic changes, at close to 100 days of age, mitochondrial dysfunction and calcium overload were maximal. There was a transient improvement during the healing stage, but the situation deteriorated with the occurrence of circulatory failure. Since the mitochondrial respiratory pattern and calcium overload parallel the cardiac degeneration, it is inferred that the cell energy depletion is a functional consequence of an abnormal calcium influx.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7057802     DOI: 10.1002/mus.880050106

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  11 in total

Review 1.  Physiological role of mitochondrial Ca2+ transport.

Authors:  R G Hansford
Journal:  J Bioenerg Biomembr       Date:  1994-10       Impact factor: 2.945

Review 2.  In situ study of myofibrils, mitochondria and bound creatine kinases in experimental cardiomyopathies.

Authors:  V Veksler; R Ventura-Clapier
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

3.  Modification of aortic contractility in the cardiomyopathic hamster.

Authors:  E C Dumont; C Lambert; D Lamontagne
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 4.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

5.  Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.

Authors:  R Sethi; N Bector; N Takeda; M Nagano; G Jasmin; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1994-11-23       Impact factor: 3.396

6.  Identification of a new missense mutation in the mtDNA of hereditary hypertrophic, but not dilated cardiomyopathic hamsters.

Authors:  Marilena Minieri; Mara Zingarelli; Huda Shubeita; Alba Vecchini; Luciano Binaglia; Felicia Carotenuto; Cristina Fantini; Roberta Fiaccavento; Laura Masuelli; Anna Coletti; Lucilla Simonelli; Andrea Modesti; Paolo Di Nardo
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

7.  Altered distribution of myosin isoenzymes in the cardiomyopathic Syrian hamster (BIO 8.262).

Authors:  V Wiegand; E Stroh; A Henniges; K Lossnitzer; H Kreuzer
Journal:  Basic Res Cardiol       Date:  1983 Nov-Dec       Impact factor: 17.165

8.  Role of mitochondrial calcium transport in the control of substrate oxidation.

Authors:  R G Hansford; D Zorov
Journal:  Mol Cell Biochem       Date:  1998-07       Impact factor: 3.396

9.  Kinetic changes of ethanolamine base exchange activity and increase of viscosity in sarcolemmal membranes of hamster heart during development of cardiomyopathy.

Authors:  A Vecchini; L Binaglia; P Di Nardo; M Bartoli; M Minieri; G Tallarida
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

10.  Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts.

Authors:  P T Buser; S Y Wu; W W Parmley; G Jasmin; J Wikman-Coffelt
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.